DISCOVER ANTIBODIES WIDER, DEEPER & FASTER
WITH AbTHENEUM™

An innovative approach to isolate sought-after antibodies
for precision medicine applications by direct interrogation of immune cells

CONTACT US

Unrivaled Immune Response Analysis for Your Next Target

Thousands Of
Antibodies

Thousands Of
Antibodies

SCT discovers thousands of antigen specific antibodies, clusters them into putative epitope groups, and provides binding data paired to full sequences

Massive
Informatics

Massive
Informatics

Our bioinformatic experts and proprietary algorithms find the best antibody candidates from thousands of sequences to streamline downstream processing

An Entirely New
Approach

An Entirely New
Approach

By combining molecular biology with Silicon Valley developed wafer and optical technologies, we’ve reinvented the way antibodies are discovered

Intellectual
Property

Intellectual
Property

SCT has broad and fundamental patents on associating antibody sequences with their phenotype in a massively parallel and scalable process

Perfect
Partner

Perfect
Partner

SCT decreases time-to-market and increases success of your next antibody campaign

Single Cell Technology® (SCT) independently developed a new generation of antibody discovery platform AbTheneum™. Intellectual property rights (currently 11 issued patents) are exclusively owned in the U.S.A., Canada, the European Union, Japan, South Korea, India, and Australia.

VIEW SCIENCE AND TECH

SCT’s platform combines micro-fabrication, next generation DNA sequencing (NGS), molecular biology, mechanical engineering, and bioinformatics together with patents and trade secrets. Output from AbTheneum™ is displayed as a compendium of Big Data in what is called the Antibody Atlas™. Each study focused on a different target protein has its own proprietary Antibody Atlas™.

Successful antibody discovery campaigns start with a wide selection of high affinity monoclonals representing diverse epitopes to the target. AbTheneum™ is designed to provide more results in less time than the technologies commonly used today, namely hybridoma technology and phage display.

SCT Leadership
Team

Passionate people.
Bright ideas.
Brilliant implementation.

VIEW THE ENTIRE TEAM

Chun-Nan Chen, Ph.D.

CEO and CSO, Board of Directors

Allison Schulkins

COO

Leyan (Joy) Tang

CTO

 

We are not

  • Another hybridoma or phage display company
  • Spreading cells on a surface, e.g.: SLAM (Selected Lymphocyte Antibody Method)
  • Sorting cells, depositing single cells in a tray, and performing RT-PCR
  • Using a micromanipulator to pull out potentially interesting cells